Werewolf Therapeutics Announces Q1 2025 Financial Results

The latest update is out from Werewolf Therapeutics ( (HOWL) ).

On May 8, 2025, Werewolf Therapeutics announced its first quarter 2025 financial results and business updates, highlighting significant progress in its clinical programs. The company is on track with its WTX-124 Phase 1/1b trial, expecting data readouts and FDA interactions later in the year, and has initiated a Phase 1b/2 trial for WTX-330. Werewolf is also advancing its INDUCER T cell engager molecules, with a development candidate expected by mid-2025, and maintains a cash runway into the fourth quarter of 2026.

Spark’s Take on HOWL Stock

According to Spark, TipRanks’ AI Analyst, HOWL is a Neutral.

Werewolf Therapeutics is navigating significant financial challenges, including ongoing losses and negative cash flows, which heavily impact its stock score. The technical indicators show a bearish trend without significant momentum. Valuation metrics are stressed, reflecting the financial difficulties. Overall, the stock score is low, indicating substantial risks associated with the company’s current financial and market position.

To see Spark’s full report on HOWL stock, click here.

More about Werewolf Therapeutics

Werewolf Therapeutics, Inc. is an innovative biopharmaceutical company focused on developing conditionally activated therapeutics to stimulate the immune system for treating cancer and other immune-mediated conditions. The company leverages its proprietary PREDATOR® platform to design molecules that activate selectively in the tumor microenvironment, with its leading clinical-stage products being WTX-124 and WTX-330, targeting solid tumors.

Average Trading Volume: 270,139

Technical Sentiment Signal: Sell

Current Market Cap: $41.69M

For detailed information about HOWL stock, go to TipRanks’ Stock Analysis page.